Cryoablation for Monomorphic Ventricular Tachycardia (VTS) (FULCRUM-VT)
Cryoablation for Monomorphic Ventricular Tachycardia IDE Study
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
Interventio / Hoito
Interventio / Hoito
Yksityiskohtainen kuvaus
A prospective, single-arm, multi-center, open label, pre-market, clinical study designed to provide safety and efficacy data regarding the use of the Adagio System in the treatment of scar-mediated SMVT in ischemic and non-ischemic patients. Study subjects will include patients who experience recurrent SMVT and are scheduled for an endocardial VT ablation. Study subjects must have an Implantable Cardioverter Defibrillator (ICD) prior to the cryoablation procedure.
The VTS study is being initiated to collect safety and effectiveness data and support future PMA supplement marketing application.
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Ilmoittautuminen
Vaihe
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
Opiskeluyhteys
- Nimi: Doug Kurschinski
- Sähköposti: dkurschinski@adagiomedical.com
Tutki yhteystietojen varmuuskopiointi
- Nimi: Nabil Jubran, MS
- Puhelinnumero: 207 949 329 2494
- Sähköposti: njubran@adagiomedical.com
Opiskelupaikat
-
-
-
Montreal, Kanada
- Rekrytointi
- Montreal Hear Institute
-
Ottaa yhteyttä:
- Katia Dydra, MD
-
-
Quebec
-
Montreal, Quebec, Kanada, H3G 1A4
- Rekrytointi
- McGill University Health Centre (MUHC), Montreal General Hospital (MGH)
-
Ottaa yhteyttä:
- Atul Verma, MD
-
-
-
-
Arizona
-
Phoenix, Arizona, Yhdysvallat, 85006
- Rekrytointi
- Banner University Medical Center Phoenix
-
-
California
-
Long Beach, California, Yhdysvallat, 90806
- Rekrytointi
- MemorialCare Long Beach Medical Center
-
Ottaa yhteyttä:
- Mark Lee, MD
- Puhelinnumero: (562) 933-2000
- Sähköposti: markyounglee@gmail.com
-
-
Massachusetts
-
Boston, Massachusetts, Yhdysvallat, 02115
- Rekrytointi
- Brigham and Women's Hospital
-
-
New York
-
Staten Island, New York, Yhdysvallat, 10305
- Rekrytointi
- Northwell Health- Staten Island University Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Yhdysvallat, 19104
- Rekrytointi
- Hospital of University of Pennsylvania
-
-
South Carolina
-
Charleston, South Carolina, Yhdysvallat, 29403
- Rekrytointi
- Medical Center of South Carolina (MUSC)
-
-
Tennessee
-
Nashville, Tennessee, Yhdysvallat, 37232
- Rekrytointi
- Vanderbilt University Medical Center
-
-
Virginia
-
Richmond, Virginia, Yhdysvallat, 23219
- Rekrytointi
- Virginia Commonwealth University
-
Ottaa yhteyttä:
- Ajay Pillai, MD
- Sähköposti: ajay.pillai@vcuhealth.org
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Kuvaus
Inclusion Criteria:
- IC 1 Male or female ≥ 18 years
- IC 2 Patients with a clinical indication for catheter ablation due to ischemic and/or non-ischemic heart disease and recurrent symptomatic sustained scar-mediated monomorphic Ventricular Tachycardia.
IC 3 Any of the following:
- Ischemic cardiomyopapthy (ICM) patients with prior history of myocardial infarction with Q waves, focal wall motion abnormality on imaging, fixed perfusion defect correlating with coronary stenosis or prior coronary intervention, 20% ≤ LVEF < 50%.
- non-ischemic cardiomyopathy (NICM) patients with scar in a territory without coronary stenosis as evidenced by CMR imaging within the prior 90 days or intra-procedurally using EAM and PES prior to investigational device use, 20% ≤ LVEF < 50%
- Arrhythmogenic right ventricular cardiomyopathy (ARVC)
- IC 4 Has received a market-released ICD prior to enrollment
- IC 5 Patient has had at least 1 documented spontaneous episode of SMVT within the previous 6 months
- IC 6 Refractory to, or intolerant of, at least one Class III AAD. (Refractory or intolerant defined as AAD failure due to recurrent VT, not tolerated/ desired due to side effects)
- IC 7 Willingness, ability, and commitment to participate in baseline and follow-up evaluations for the full length of the study
- IC 8 Willingness and ability to give an informed consent
Exclusion Criteria:
- EC 1 Intracardiac thrombus by TTE or TEE within 48 hours prior to the procedure
- EC 2 Presence of isolated epicardial scar(s) requiring epicardial ablation identified by either preoperative CMR imaging within 90 days of procedure or intra-procedurally using EAM and PES prior to investigational device use
EC 3 VTs due to any of the following causes:
- Idiopathic VT
- Automaticity or triggered activity
- Bundle Branch Reentry (BBR)
- Any focal tachycardia (e.g., papillary, RVOT)
- Ventricular tachycardia secondary to electrolyte imbalance, active thyroid disease, or any other reversible or non-cardiac cause
EC 4 NICM patients only, if any of the following apply:
- Congenital condition that limits access to the left or right ventricles
- Severe aortic or mitral stenosis, severe mitral regurgitation, or severe aortic insufficiency
- Active inflammatory processes (e.g., myocarditis) within the past 120 days
- Sarcoidosis
- Hypertrophic cardiomyopathy
- Drug- or alcohol-induced cardiomyopathy
- EC 5 Any VT ablation within 4 weeks prior to enrollment
- EC 6 More than one prior (>4 weeks) VT ablation or prior surgical treatment for VT within the past 2 years
- EC 7 Cardiogenic shock, unless it is due to incessant monomorphic VT
EC 8 Any other cardiovascular conditions as described below:
- Class IV heart failure
- Aortic aneurysm
- Previous cardiac surgery or percutaneous coronary intervention within 60 days prior to index procedure
- Interatrial baffle, closure device, patch, or PFO occlusion device
- Coronary artery bypass graft (CABG) procedure within six (6) months prior to the ablation procedure
- Acute MI or unstable angina in the previous 60 days
- Mechanical mitral or aortic valve
- Cardiac myxoma
- Significant congenital heart disease
- EC 9 Acute illness or active systemic infection
- EC 10 Any previous history of cryoglobulinemia
- EC 11 History of blood clotting or bleeding disease
- EC 12 Peripheral vascular disease that precludes LV access
- EC 13 Contraindication to heparin
- EC 14 Allergy to radiographic contrast dye that cannot be medically managed prior to the ablation procedure
- EC 15 Any prior history of documented cerebral vascular accident (CVA), TIA or systemic embolism (excluding a post-operative Deep Vein Thrombosis, DVT), within 6 months prior to the ablation procedure.
- EC 16 Pregnant, or anticipated pregnancy during study follow-up
- EC 17 Current enrollment in any other study protocol where testing or results from that study may interfere with the procedure or outcome measurements for this study
- EC 18 Any other condition (e.g., ARVC with extensive free wall scarring) that, in the judgment of the investigator, makes the patient a poor candidate for this procedure, the study or compliance with the protocol (includes vulnerable patient population, mental illness, addictive disease, candidate for heart transplantation, patient with ventricular assist device, or terminal illness with a life expectancy less than 12 months)
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseiden lukumäärä
Aseet ja interventiot
Osallistujaryhmä / ArmOsallistujaryhmä / Arm |
Interventio / HoitoInterventio / Hoito |
|---|---|
|
Kokeellinen: VT Cryoablation
all enrolled patients will have a ablation procedure using the vCLAS Ventricular Ablation System (VTS Catheter and Console) for SMVT
|
ablation procedure using the investigational device (vCLAS Ventricular Ablation System including VTS Catheter and Console)
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Primary Safety Endpoint - Freedom from definite or probable device or procedure related Major Adverse Events (MAEs) that occur within 7 days following the ablation procedure.
Aikaikkuna: 7 days following the ablation procedure
|
Primary Safety Endpoint is freedom from definite or probable device or procedure related Major Adverse Events (MAEs) that occur within 7 days following the ablation procedure. Events will be adjudicated by an independent Clinical Events Committee (CEC). MAEs include any of the following: • Death • Acute myocardial infarction • Cardiac perforation/pericardial tamponade • Cerebral infarct or systemic embolism • Major bleeding requiring transfusion • Acute Mitral, Tricuspid or Aortic valve damage resulting in moderate or severe regurgitation • Access site complications requiring medical or surgical intervention • Pericarditis • Heart block requiring a permanent pacemaker • Other serious adverse device effects (SADEs), including TIAs, adjudicated by an independent Clinical Events Committee (CEC) to be probably or definitely related to the Adagio System. |
7 days following the ablation procedure
|
|
Primary Efficacy Endpoint - Freedom from recurrent sustained MMVT in the absence of a new AAD or increase in dose of a pre-ablation AAD for VT management at 6 months following the ablation procedure
Aikaikkuna: 6 months after the procedure
|
Primary Efficacy Endpoint is defined as freedom from recurrent sustained MMVT in the absence of a new AAD or increase in dose of a pre-ablation AAD for VT management at 6 months following the ablation procedure, where sustained MMVT is defined as continuous MMVT for > 30 seconds (programmed monitoring zone only), or MMVT requiring appropriate ICD intervention regardless of duration.
All ICD interrogation reports will be adjudicated by an independent VT Event Committee (VTEC) to support the primary efficacy endpoint.
|
6 months after the procedure
|
|
Primary Procedural Endpoint - Percentage of non-inducibility VT targeted for ablation post-procedure
Aikaikkuna: at the end of the ablation procedure
|
Primary Procedural Endpoint is defined as non-inducibility of any VT targeted for ablation at the end of the procedure
|
at the end of the ablation procedure
|
Toissijaiset tulostoimenpiteet
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Secondary Safety Endpoint - Freedom from definite or probable device or procedure related Serious Adverse Events (SAEs) within 12 months following the ablation procedure
Aikaikkuna: 12-months post ablation procedure
|
Secondary Safety Endpoint is defined as freedom from definite or probable device or procedure related Serious Adverse Events (SAEs) within 12 months following the ablation procedure.
Events will be adjudicated by an independent Clinical Events Committee (CEC).
|
12-months post ablation procedure
|
|
Secondary Efficacy Endpoint - Freedom from VT greater than 30 seconds or appropriate ICD intervention at 12 months
Aikaikkuna: 12-months post ablation procedure
|
Secondary Efficacy Endpoint is defined as freedom from Ventricular Tachycardia lasting longer than 30 seconds or appropriate ICD intervention at 12 months
|
12-months post ablation procedure
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Opiskelun aloitus
Ensisijainen valmistuminen (Arvioitu)
Ensisijainen valmistuminen
Opintojen valmistuminen (Arvioitu)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- CS-300 Rev.H
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .